# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-040493
Filing Date
2023-11-13
Accepted
2023-11-13 16:06:53
Documents
65
Period of Report
2023-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 |  | form10-q.htm iXBRL | 10-Q | 1225925
2 |  | ex31-1.htm | EX-31.1 | 9393
3 |  | ex31-2.htm | EX-31.2 | 11497
4 |  | ex32-1.htm | EX-32.1 | 10082
| Complete submission text file | 0001493152-23-040493.txt |  | 6217550

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL SCHEMA FILE | envb-20230930.xsd | EX-101.SCH | 54442
6 | XBRL CALCULATION FILE | envb-20230930_cal.xml | EX-101.CAL | 56517
7 | XBRL DEFINITION FILE | envb-20230930_def.xml | EX-101.DEF | 208911
8 | XBRL LABEL FILE | envb-20230930_lab.xml | EX-101.LAB | 424732
9 | XBRL PRESENTATION FILE | envb-20230930_pre.xml | EX-101.PRE | 318855
59 | EXTRACTED XBRL INSTANCE DOCUMENT | form10-q_htm.xml | XML | 1008650

Mailing Address 4851 TAMIAMI TRAIL N, SUITE 200 NAPLES FL 34103
Business Address 4851 TAMIAMI TRAIL N, SUITE 200 NAPLES FL 34103 239-302-1707
Enveric Biosciences, Inc. (Filer) CIK: 0000890821 (see all company filings)

EIN.: 954484725 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38286 | Film No.: 231398671
SIC: 2834 Pharmaceutical Preparations